CYP2D6 is one of the most important detox enzymes. It is responsible for the clearance of 20% of clinical drugs, including opioids (codeine, tramadol), antitumor drugs (tamoxifen), antidepressants (fluoxetine), and antipsychotics (haloperidol). In addition, this enzyme also metabolizes dopamine and serotonin. Therefore, it doesn’t come as a surprise that the activity of this enzyme can be associated with human personality, behavior traits, and psychiatric disease susceptibility. Read on to find out more about CYP2D6 function, gene variants, and supplements that increase or decrease enzyme activity.
What is CYP2D6?
CYP2D6 is one of the cytochrome P450 monooxygenases (CYPs). These are enzymes that eliminate most of the drugs and toxins from the human body (R).
This enzyme metabolizes:
- Opioids: morphine (R), hydrocodone (R), codeine (R), oxycodone (R), tramadol (R).
- Antidepressants: amitriptyline, nortriptyline, venlafaxine, and fluoxetine (R, R, R).
- Antipsychotics: haloperidol (R), risperidone (R).
- Atomoxetine (used to treat ADHD) (R).
- Beta-blockers: carvedilol and metoprolol (R).
- Antimalarials: primaquine and carboxy-primaquine (R).
- Antiemetics: metoclopramide (R).
- Antitumor agents: tamoxifen and gefitinib (R, R).
- Methamphetamine (MDMA) (R).
- Metabolizes tyramine to dopamine (R).
- Regenerates serotonin (R).
- Inactivates neurotoxins (R, R).
- Metabolizes the antioxidant tyrosol, found in olive oil (R).
Four metabolizer types are used to describe CYP2D6 activity in individuals:
- ultra-rapid metabolizer
- extensive metabolizer
- intermediate metabolizer
- poor metabolizer (R)
The activity of your CYP2D6 should be taken into account when administering a number of drugs. For example, a poor metabolizer should not be given codeine since the drug would have no effect. Conversely, an ultra-rapid metabolizer would likely suffer side effects from a normal dose (R).
Apart from the liver, this enzyme is also found in the brain (R).
CYP2D6 The Good
This enzyme influences dopamine and serotonin levels in the brain. That explains why the activity of CYP2D6 has been associated with different personality traits (R).
Further, those with reduced enzyme activity had a tendency to higher impulsivity (novelty seeking) (R).
Low enzyme activity is also associated with autoimmune diseases (meta-analysis, 12 studies, 1,472 patients, and 3,328 controls) (R).
CYP2D6 The Bad
Poor metabolizers have higher conscientiousness/responsibility, orderliness, and the pursuit of achievement through perseverance (R).
Higher CYP2D6 activity was associated with heavier smoking. Poor metabolizers had a lower risk of becoming heavy smokers (1230 subjects) (R).
Suicide attempters carrying two or more active CYP2D6 genes were more likely to be diagnosed with one or more personality disorders (342 subjects) (R).
CYP2D6 Gene Polymorphism
- Normal enzyme function variants (e.g. *1 and *2) (R, R).
- Reduced function variants (e.g. *9, *10, and *41) (R, R).
- Nonfunctional variants (e.g. ∗3, ∗4, ∗5, and ∗6) (R, R).
It gets more complicated, however, because this gene can also be missing, or multiplied. This means that you can have 0, 1, 2, or more than 2 copies of the gene. Therefore, most clinical laboratories also report the copy number (R).
CYP2D6*5 represents a gene deletion (no gene present). Gene duplications and multiplications are denoted by “xN” (e.g., CYP2D61xN with xN representing the number of gene copies) (R).
How often do people have more or less of the usual two copies of this gene?
In a set of over 30 000 clinical samples, 12.6% had zero, one, or three or more copies of the CYP2D6 gene (R).
If you are a poor metabolizer, you are more prone to adverse effects from taking antidepressants (46 studies) (R).
People with ultra-rapid metabolism are less frequent in Northern Europe, North America, and Asia (1–5%). They are more common in the Mediterranean (7–12%), Saudi-Arabia (21%), and Ethiopia (29%) (R).
rs3892097 is also known as the CYP2D6*4 variant. This is the most frequent variant in Europeans and North Americans (18.0%). It accounts for 70%–90% of all nonfunctional enzyme cases (R).
This variant (A) increases the risk of developing systemic sclerosis (296 and 206 subjects) (R, R), Alzheimer’s disease (2018 subjects) (R), and Parkinson’s disease (meta-analysis, 2629 patients, and 3601 controls ) (R).
The carriers of this variant are more susceptible to pesticide toxicity (59 subjects) (R).
This variant increases weight gain as a side effect of antipsychotics (81 patients) (R).
Increasing or Decreasing CYP2D6
These increase CYP2D6:
These decrease CYP2D6:
- Starfruit juice (R)
- Aloe vera juice (R)
- Kale (R)
- St. John’s wort (R)
- Goldenseal (R)
- Fennel (R)
- Garden cress seed extract (R)
- Curcuma (R)
- Asafetida (R)
- Berberine (R, R)
- Quercetin (R, R)
- Caffeic acid (R)
- Gallic acid and ellagic acid (R, R)
- The leaves of the lotus plant (Nelumbo nucifera) (R, R)
- Raspberry leaf (R)
- Licochalcone A, a major compound in traditional Chinese herbal licorice (R)
- Black pepper fruit and arylamides isolated from black pepper (Piper nigrum) (R, R)
- Paroxetine (R, R), melperone (R), and sarpogrelate (R)
- Tetrahydrocannabinol, cannabidiol (CBD), and cannabinol (found in marijuana) (R)
- Chronic kidney disease (R)